Stock Analysis on Net

Boston Scientific Corp. (NYSE:BSX)

$22.49

This company has been moved to the archive! The financial data has not been updated since May 4, 2023.

Analysis of Solvency Ratios
Quarterly Data

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Solvency Ratios (Summary)

Boston Scientific Corp., solvency ratios (quarterly data)

Microsoft Excel
Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Debt Ratios
Debt to equity
Debt to capital
Debt to assets
Financial leverage
Coverage Ratios
Interest coverage

Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).


Debt to Equity Ratio
The debt to equity ratio showed moderate fluctuations over the observed period. Initially around 0.82 to 0.84 in early 2018, it peaked at 1.12 in late 2019, indicating a temporary increase in reliance on debt relative to equity. Subsequently, the ratio declined steadily from the end of 2019 through early 2023, reaching about 0.50, suggesting an improvement in the company's capital structure with lower leverage relative to equity.
Debt to Capital Ratio
This ratio followed a similar trend to the debt to equity ratio. It started at approximately 0.45 in early 2018, rose to 0.53 in late 2019, and then gradually decreased to around 0.34 by the first quarter of 2023. This decline indicates a reduced proportion of debt within the company’s total capital base over time.
Debt to Assets Ratio
The debt to assets ratio increased from 0.30 to 0.41 between early 2018 and late 2019, reflecting an increased share of debt financing in the total asset base during that timeframe. Post-2019, the ratio declined consistently to approximately 0.27 by early 2023, indicating a stabilizing asset base with less reliance on debt funding relative to total assets.
Financial Leverage
Financial leverage, expressed as a ratio, exhibited volatility during the period. It decreased from 2.73 in early 2018 to 2.20 by late 2019, indicating a reduction in the use of debt or equity financing impact on assets. This ratio further declined progressively to a low near 1.84 by early 2023, suggesting a significant decrease in total leverage, improving financial stability.
Interest Coverage Ratio
The interest coverage ratio data is incomplete for early periods but begins at 6.90 in late 2018 and shows a downward trend through 2020, reaching very low levels near 0.12 by the end of that year. This sharp decrease implies decreased earnings relative to interest expenses, signaling potential difficulty in meeting interest obligations during that period. However, from 2021 onwards, the ratio improved markedly, rising back to 6.58 by early 2023. This recovery suggests strengthened operational earnings and improved ability to cover interest payments.

Debt Ratios


Coverage Ratios


Debt to Equity

Boston Scientific Corp., debt to equity calculation (quarterly data)

Microsoft Excel
Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in millions)
Current debt obligations
Long-term debt
Total debt
 
Stockholders’ equity
Solvency Ratio
Debt to equity1
Benchmarks
Debt to Equity, Competitors2
Abbott Laboratories
CVS Health Corp.
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q1 2023 Calculation
Debt to equity = Total debt ÷ Stockholders’ equity
= ÷ =

2 Click competitor name to see calculations.


Total Debt
The total debt exhibited a general rising trend from March 2018 through the end of 2019, increasing from $5,765 million to a peak of $10,887 million in September 2019. After this peak, the total debt stabilized somewhat, fluctuating between approximately $9,000 million and $10,300 million through 2020. Starting in 2021, the debt levels showed a gradual decline, reaching a low point around $8,584 million in September 2022, before a slight uptick toward early 2023.
Stockholders’ Equity
Stockholders’ equity demonstrated consistent growth over the entire period. Beginning at $7,030 million in March 2018, the equity base increased steadily, with particularly significant jumps seen around the end of 2019, where equity surged from $9,699 million in September 2019 to $13,877 million in December 2019. This growth trend continued post-2019, reaching $17,850 million by March 2023, indicating strengthening shareholder capital over the assessed periods.
Debt to Equity Ratio
The debt to equity ratio showed substantial variability aligned with changes observed in debt and equity. Initially, the ratio was around 0.8 from early 2018 into late 2018. It spiked to 1.12 in September 2019, reflecting a period when debt growth outpaced equity. However, following this peak, there was a notable decline in the ratio, stabilizing near 0.6 during 2020. From 2021 onward, the ratio gradually decreased further, approaching approximately 0.5 by early 2023, indicating a strengthening equity position relative to debt and a more conservative leverage posture over recent quarters.
Overall Insights
The data indicate a period of increasing leverage through 2019, with debt rising faster than equity, followed by substantial equity growth which reversed the leverage trend. The steady equity increase paired with controlled debt levels since 2020 results in a healthier capital structure, demonstrated by declining debt to equity ratios. This suggests improving financial stability and potentially increased capacity for absorbing financial shocks or funding growth initiatives with lower financial risk.

Debt to Capital

Boston Scientific Corp., debt to capital calculation (quarterly data)

Microsoft Excel
Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in millions)
Current debt obligations
Long-term debt
Total debt
Stockholders’ equity
Total capital
Solvency Ratio
Debt to capital1
Benchmarks
Debt to Capital, Competitors2
Abbott Laboratories
CVS Health Corp.
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q1 2023 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =

2 Click competitor name to see calculations.


The analysis of the quarterly financial data reveals several notable trends concerning the company's leverage and capital structure over the observed period.

Total debt

Total debt showed an overall increasing trend from March 31, 2018, through the end of 2019, rising from approximately 5.8 billion USD to a peak near 10.9 billion USD in September 2019. This increase indicates a period of expanding borrowing or refinancing activities. Following this peak, the debt level stabilized and then experienced a gradual decline throughout 2020 and 2021, averaging around 9.1 billion USD to 9.2 billion USD. In 2022 and early 2023, total debt fluctuated moderately between roughly 8.6 billion USD and 9.3 billion USD, suggesting relatively stable debt management in the recent period. Overall, there was a reduction from the peak levels seen in 2019 but total debt remains elevated relative to the starting point in 2018.

Total capital

Total capital consistently increased across the entire timeframe, starting at about 12.8 billion USD in early 2018 and advancing steadily to around 26.9 billion USD by March 31, 2023. The most rapid growth occurred between 2018 and 2020, where total capital nearly doubled, reflecting either significant equity infusions, retained earnings growth, or a combination of capital structure strengthening activities. The growth rate somewhat moderated after 2020 but maintained a steady upward trajectory, indicating continued capital base expansion.

Debt to capital ratio

The debt to capital ratio, a key leverage metric, exhibited notable fluctuations. Initially, this ratio hovered around 0.44-0.46 through early 2018 until late 2018, before rising to approximately 0.50-0.53 during mid to late 2019, which corresponds with the peak debt levels observed. This indicates a higher proportion of debt in the capital structure during that period. Following this, the leverage ratio decreased significantly beginning in late 2019 and through 2021, reaching a low near 0.35. This decline suggests improvements in capital structure through either debt repayments or stronger growth in equity and total capital compared to debt. From 2022 onwards, the ratio slightly fluctuated between 0.33 and 0.36, reflecting a relatively stable and moderate leverage position.

In summary, the financial data indicates that the company experienced an increase in debt levels up to 2019 followed by a gradual deleveraging phase. Concurrently, total capital expanded robustly throughout the period, leading to a reduced leverage ratio after 2019 and suggesting a strategic emphasis on strengthening the capital base and managing debt prudently. The overall lower and more stable debt to capital ratio in recent years points to a more balanced and potentially less risky capital structure moving forward.


Debt to Assets

Boston Scientific Corp., debt to assets calculation (quarterly data)

Microsoft Excel
Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in millions)
Current debt obligations
Long-term debt
Total debt
 
Total assets
Solvency Ratio
Debt to assets1
Benchmarks
Debt to Assets, Competitors2
Abbott Laboratories
CVS Health Corp.
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q1 2023 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =

2 Click competitor name to see calculations.


Total Debt
The total debt increased steadily from March 2018 to December 2019, peaking at 10,887 million USD in September 2019. From this peak, debt levels generally declined through the end of 2020 and mostly stabilized around 9,000 million USD in 2021 and 2022. There is a slight increase observed again by March 2023, reaching 9,005 million USD.
Total Assets
Total assets showed a consistent upward trend over the entire period. Starting at 19,202 million USD in March 2018, assets grew steadily, with notable acceleration between June 2019 and December 2019, reaching over 30,000 million USD. Subsequent quarters showed relatively stable asset levels, narrowly fluctuating around the 31,000 million USD mark, and reaching the highest value of 32,892 million USD by March 2023.
Debt to Assets Ratio
The debt to assets ratio increased from 0.30 in March 2018 to a high of 0.41 in September 2019, reflecting a period where debt grew faster than assets. However, post-September 2019, there was a notable improvement as the ratio declined steadily, reaching 0.27 by March 2023. This indicates a reduction in leverage relative to asset base over these later periods, suggesting improved financial stability or deleveraging efforts.
Summary Insights
Overall, the financial data reveal an initial phase of increasing leverage with rising debt and increasing debt-to-assets ratio until late 2019. After this period, the company demonstrates a trend toward greater asset accumulation with a concurrent reduction in leverage. The stabilization and slight decrease in total debt starting in late 2019 alongside continuous asset growth contribute to a lower debt to asset ratio. This pattern suggests strategic management toward strengthening the balance sheet and improving solvency metrics over the more recent quarters.

Financial Leverage

Boston Scientific Corp., financial leverage calculation (quarterly data)

Microsoft Excel
Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in millions)
Total assets
Stockholders’ equity
Solvency Ratio
Financial leverage1
Benchmarks
Financial Leverage, Competitors2
Abbott Laboratories
CVS Health Corp.
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q1 2023 Calculation
Financial leverage = Total assets ÷ Stockholders’ equity
= ÷ =

2 Click competitor name to see calculations.


The analysis of the quarterly financial data reveals distinct trends in total assets, stockholders’ equity, and financial leverage over the examined period.

Total assets
Total assets demonstrated a general upward trajectory from March 2018 through March 2023, increasing from $19,202 million to $32,892 million. The growth was relatively steady, with occasional acceleration notably during the latter part of 2019, where total assets rose from $26,756 million in September to $30,565 million by December. Following this spike, total assets maintained a level slightly above $30 billion with incremental increases, indicating continued asset growth but at a moderated pace.
Stockholders’ equity
Stockholders’ equity also showed consistent growth over the period, rising from $7,030 million in March 2018 to $17,850 million by March 2023. Noteworthy is the jump from $9,699 million in September 2019 to $13,877 million in December 2019, paralleling the surge in total assets during the same timeframe. After this considerable increase, equity continued to increase gradually, supporting asset growth and reflecting strengthening capital base.
Financial leverage
The financial leverage ratio exhibited a notable decreasing trend throughout the time frame, declining from 2.73 in March 2018 to 1.84 in March 2023. This decline indicates a reduction in reliance on debt relative to equity, suggesting improved financial stability and a stronger equity position in proportion to total assets. The most significant reduction occurred post-2019, aligning with the sharp rise in equity that outpaced total asset growth, resulting in lower leverage values.
Overall trends and insights
Across the periods examined, the company expanded its total asset base by approximately 71%, paired with more than doubling stockholders’ equity. This simultaneous growth indicates a strategic strengthening of the financial position, with less dependence on debt financing as evidenced by the falling financial leverage ratio. The marked increases near the end of 2019 likely reflect substantial financial or operational events leading to expansion and enhanced capitalization. The more moderate growth after 2020 suggests a period of stabilization, maintaining robust asset levels and a solid equity foundation while continuing to optimize the financial structure.

Interest Coverage

Boston Scientific Corp., interest coverage calculation (quarterly data)

Microsoft Excel
Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in millions)
Net income (loss)
Add: Income tax expense
Add: Interest expense
Earnings before interest and tax (EBIT)
Solvency Ratio
Interest coverage1
Benchmarks
Interest Coverage, Competitors2
Abbott Laboratories
CVS Health Corp.
Elevance Health Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q1 2023 Calculation
Interest coverage = (EBITQ1 2023 + EBITQ4 2022 + EBITQ3 2022 + EBITQ2 2022) ÷ (Interest expenseQ1 2023 + Interest expenseQ4 2022 + Interest expenseQ3 2022 + Interest expenseQ2 2022)
= ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


The earnings before interest and tax (EBIT) demonstrate notable fluctuations over the analyzed quarterly periods. Starting at 384 million US dollars in the first quarter of 2018, EBIT increased to a peak of 566 million in the first quarter of 2019. Thereafter, a downward trend was observed throughout 2019, bottoming out at 174 million in the fourth quarter. The first three quarters of 2020 show negative EBIT values, with the lowest point recorded at -141 million US dollars in the third quarter, before rebounding sharply to 403 million in the fourth quarter of 2020. From 2021 onwards, EBIT figures exhibited volatility but largely recovered to consistently positive values, reaching 569 million in the third quarter of 2021 and maintaining relatively high levels with 509 million recorded in the first quarter of 2023.

Interest expense has shown increasing variance over the period. It began at 61 million US dollars in the first quarter of 2018 and generally fluctuated between 57 and 96 million until late 2021. Notably, the first quarter of 2022 displays a sharp spike to 279 million, which is an exceptional increase relative to prior quarters. Following this spike, interest expense returned to the previous range between 63 and 87 million throughout the remainder of 2022 and into early 2023.

The interest coverage ratio, which measures the EBIT relative to interest expense, reflects the combined impact of changes in EBIT and interest expense. Early in the timeline, around late 2018 and early 2019, the ratio ranged from approximately 6.9 to 3.76, signifying strong coverage. A significant decline occurred throughout 2019 and 2020, with the ratio dropping to as low as 0.12 in the fourth quarter of 2020, indicating weakened ability to cover interest expenses. An improvement trend commenced from 2021 onwards, increasing the ratio to over 6 by the first quarter of 2023. The marked dip below 1.0 in 2020 corresponds with the period of negative EBIT and elevated risk profile. Despite the spike in interest expense in early 2022, the interest coverage ratio remained above 2, showing some resilience.

Overall, the data reveals cyclical operational performance with a significant contraction in 2020, followed by a recovery. Interest expenses exhibit an anomalous spike in early 2022 that may warrant further investigation. The interest coverage ratio aligns with these trends, highlighting periods of elevated financial stress during 2019 and 2020, with subsequent recovery demonstrating improved capacity to meet interest obligations.